Tempus

OverviewSuggest Edit

Tempus Labs is a genomics and data-analytics company. It works with doctors and patients to use genomic data to more effectively choose treatment options based on outcomes from other patients.
TypePrivate
Founded2015
HQChicago, IL, US
Websitetempus.com
Employee Ratings3.5

Latest Updates

Employees (est.) (May 2022)1,549(+2%)
Job Openings236
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Tempus

Eric Lefkofsky

Eric Lefkofsky

Founder, CEO
Shane Colley

Shane Colley

Chief Technology Officer
Joel Dudley

Joel Dudley

Chief Scientific Officer
Jim Rogers

Jim Rogers

Chief Financial Officer
Colette Freeman

Colette Freeman

Chief People Officer
Ryan Fukushima

Ryan Fukushima

Chief Operating Officer
Show more

Tempus Office Locations

Tempus has an office in Chicago
Chicago, IL, US (HQ)
600 W Chicago Ave #510
Show all (1)

Tempus Financials and Metrics

Summary Metrics

Founding Date

2015

Tempus total Funding

$620 m

Tempus latest funding size

$100 m

Time since last funding

2 years ago

Tempus investors

Tempus's latest funding round in March 2020 was reported to be $100 m. In total, Tempus has raised $620 m. Tempus's latest valuation is reported to be $5 b.
View all funding rounds

Tempus Revenue

Market valuation

5.0b
Show all financial metrics

Tempus Operating Metrics

May, 2020

Product Categories

5

Samples Processed per Year (Infectious Diseases)

1 m

Trademarks

14

Tempus Acquisitions / Subsidiaries

Company NameDateDeal Size
AKESOgenDecember 11, 2019

Tempus Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Tempus Online and Social Media Presence

Embed Graph

Tempus Company Culture

  • CEO Rating

    A+

    90/100

Learn more on Comparably

Tempus News and Updates

Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress

Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies

Tempus, Groupon Co-Founder's Medical Technically Startup, Is Exploring an IPO

Tempus, Groupon Co-Founder's Medical Startup, Is Exploring an IPO

Rain Therapeutics Announces Collaboration with Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

Clinical trial for MDM2 amplified cancers expected to commence in second half of 2021 Clinical trial for MDM2 amplified cancers expected to commence in second half of 2021

Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities

Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates

Tempus Resource by ProSymmetry Now Available on Carahsoft SEWP V and NASPO Contracts

Powerful Resource Management Solutions Now Available to Government Agencies Powerful Resource Management Solutions Now Available to Government Agencies
Show more

Tempus Blogs

Fortune Brainstorm Health Conference 2020 | Patients First: Transforming Care Through Disruptive Technology

Eric Lefkofsky and Dr. David Agus discuss how Tempus is leveraging data and AI to advance personalized patient care and therapeutic discovery. Video linked here. The post Fortune Brainstorm Health Conference 2020 | Patients First: Transforming Care Through Disruptive Technology appeared first on Tem…

Tempus and Geisinger Find ECG-Based AI Model Can Predict Undiagnosed Structural Heart Disease

Published in Circulation, the rECHOmmend study expands on AI-focused research to improve patient outcomes in cardiology   A team of clinicians and scientists from Tempus and Geisinger have found that a new artificial intelligence model can accurately identify patients at increased risk of undiagnose…

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines

Importance: Germline testing guidelines are suggested for specific disease types or a family history of cancer, yet alterations are found in cancer types in which germline testing is not routinely indicated. The clinical role of identifying germline variants in these populations is valuable to patie…

Tempus Launches Psychiatric Real-World Data Program to Advance Personalized Medicine

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Tempus N+, a program that aims to power precision medicine solutions through the use of real-world data for mental health. Tempus is collaborating with academic medical institutions around the country t…

Protocol for Drug Screening of Patient-Derived Tumor Organoids Using High-Content Fluorescent Imaging

Summary High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted microscopy with an automated stage, this protocol c…

Precision Health Diagnostic and Surveillance Network Uses S Gene Target Failure (SGTF) Combined With Sequencing Technologies to Track Emerging SARS-CoV-2 Variants

Introduction The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic revealed a worldwide lack of effective molecular surveillance networks at local, state, and national levels, which are essential to identify, monitor, and limit viral community spread. SARS-CoV-2 variants of conce…
Show more

Tempus Frequently Asked Questions

  • When was Tempus founded?

    Tempus was founded in 2015.

  • Who are Tempus key executives?

    Tempus's key executives are Eric Lefkofsky, Shane Colley and Joel Dudley.

  • How many employees does Tempus have?

    Tempus has 1,549 employees.

  • Who are Tempus competitors?

    Competitors of Tempus include PathAI, Prognos Health and Genomic Health.

  • Where is Tempus headquarters?

    Tempus headquarters is located at 600 W Chicago Ave #510, Chicago.

  • Where are Tempus offices?

    Tempus has an office in Chicago.

  • How many offices does Tempus have?

    Tempus has 1 office.